Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | L3MBTL3 | Q96JM7 | 3/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.33 |
| ▸ | HTR2C | P28335 | 2/20 | 0.33 |
| ▸ | HTR2B | P41595 | 2/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL65291 | 1.00 | HTR6 (1.00) | HTR6KMT2AHPGDSMN1; SMN2L3MBTL3 | |
| SCHEMBL3522066 | 1.00 | HTR6 (1.00) | HTR6KMT2AHPGDSMN1; SMN2L3MBTL3 | |
| SCHEMBL8499402 | 0.98 | HTR6 (0.96) | HTR6KMT2AHPGDSMN1; SMN2L3MBTL3 | |
| SCHEMBL398118 | 0.98 | HTR6 (0.96) | HTR6KMT2AHPGDSMN1; SMN2L3MBTL3 | |
| Hydrochloric Acid SCHEMBL63700 | 0.98 | HTR6 (0.96) | HTR6KMT2AHPGDSMN1; SMN2L3MBTL3 | |
| SCHEMBL8502194 | 0.98 | HTR6 (0.96) | HTR6KMT2AHPGDSMN1; SMN2L3MBTL3 | |
| SCHEMBL8501091 | 0.98 | HTR6 (0.96) | HTR6KMT2AHPGDSMN1; SMN2L3MBTL3 | |
| SCHEMBL8503565 | 0.98 | HTR6 (0.96) | HTR6KMT2AHPGDSMN1; SMN2L3MBTL3 | |
| Hydrochloric Acid SCHEMBL20522843 | 0.98 | HTR6 (0.96) | HTR6KMT2AHPGDSMN1; SMN2L3MBTL3 | |
| SCHEMBL6314141 | 0.96 | HTR6 (0.92) | HTR6KMT2AHPGDSMN1; SMN2L3MBTL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 142 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624053-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2026-05-12 | — | — | US | disclosed |
| US-20260070930-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT | 2026-03-12 | — | — | US | disclosed |
| EP-3623372-B1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH INC (US) | 2026-02-04 | — | — | EP | disclosed |
| US-20250388608-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2025-12-25 | — | — | US | disclosed |
| EP-4665454-A1 | IMIDAZOTRIAZINE IL-17A MODULATORS AND USES THEREOF | Dice Alpha, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20250376482-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2025-12-11 | — | — | US | disclosed |
| US-20250282762-A1 | PYRAZOLOPYRIDINE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2025-09-11 | — | — | US | disclosed |
| US-20250197423-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2025-06-19 | — | — | US | disclosed |
| US-20250145643-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2025-05-08 | — | — | US | disclosed |
| CN-119798279-A | RAS inhibitors | 锐新医药公司 | 2025-04-11 | — | — | CN | disclosed |
| US-6906060-B2 | Substituted hexahydropyrrolo[1,2-a]pyrazines, octahydropyrido[1,2-a]-pyrazines and decahydropyrazino[1,2-a]azepines | NOVO NORDISK A/S (DK) | 2005-06-14 | — | — | US | disclosed |
| EP-1513842-A1 | SUBSTITUTED HEXAHYDROPYRROLO (1,2-A)PYRAZINES, OCTAHYDROPYRIDO(1,2-A)PYRAZINES AND DECAHYDROPYRAZINO(1,2-A)AZEPINES | NOVO NORDISK A/S (DK) | 2005-03-16 | — | — | EP | disclosed |
| US-20040023946-A1 | Substituted hexahydropyrrolo[1,2-a]pyrazines, octahydropyrido[1,2-a]-pyrazines and decahydropyrazino[1,2-a]azepines | VTVX HOLDINGS II LLC | 2004-02-05 | — | — | US | disclosed |
| WO-2004000832-A1 | 1-[(INDOL-3-YL)CARBONYL] PIPERAZINE DERIVATIVES | AKZO NOBEL N.V. (NL) | 2003-12-31 | — | — | WO | disclosed |
| US-20030236259-A1 | Novel aryl- and heteroarylpiperazines | HIGH POINT PHARMACEUTICALS, LLC | 2003-12-25 | — | — | US | disclosed |
| WO-2003104235-A1 | SUBSTITUTED HEXAHYDROPYRROLO[1,2-A]PYRAZINES, OCTAHYDROPYRIDO[1,2-A]PYRAZINES AND DECAHYDROPYRAZINO[1,2-A]AZEPINES | NOVO NORDISK A/S (DK) | 2003-12-18 | — | — | WO | disclosed |
| EP-0797577-B1 | BICYCLIC NONANE AND DECANE COMPOUNDS HAVING DOPAMINE RECEPTOR AFFINITY | ALLELIX BIOPHARMA (CA) | 2000-07-26 | — | — | EP | disclosed |
| EP-0797577-A1 | BICYCLIC NONANE AND DECANE COMPOUNDS HAVING DOPAMINE RECEPTOR AFFINITY | Allelix Biopharmaceuticals Inc. (CA) | 1997-10-01 | — | — | EP | disclosed |
| US-5576314-A | Bicyclic nonane and decane compounds having dopamine receptor affinity | ALLELIX BIOPHARMACEUTICALS INC. (CA) | 1996-11-19 | — | — | US | disclosed |
| WO-1996018630-A1 | BICYCLIC NONANE AND DECANE COMPOUNDS HAVING DOPAMINE RECEPTOR AFFINITY | ALLELIX BIOPHARMACEUTICALS INC. (CA) | 1996-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260070930-A1 | RAS INHIBITORS | KRAS, NRAS, RIN1 | HTR6 4346/4885KMT2A 4067/4885HPGD 1566/4885 |
| US-20040023946-A1 | Substituted hexahydropyrrolo[1,2-a]pyrazines, octahydropyrido[1,2-a]-pyrazines and decahydropyrazino[1,2-a]azepines | HRH2, HRH4, HRH1 | HTR6 119/4885KMT2A 632/4885HPGD 754/4885 |
| US-20250145643-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | HTR6 4617/4885KMT2A 3685/4885HPGD 3002/4885 |
| US-20250376482-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNI, TOP2B | HTR6 2631/4885KMT2A 1020/4885HPGD 2495/4885 |
| US-20250282762-A1 | PYRAZOLOPYRIDINE DERIVATIVES AND USES THEREOF | HBZ, ZFX, WIZ | HTR6 3197/4885KMT2A 1734/4885HPGD 1030/4885 |
| US-20030236259-A1 | Novel aryl- and heteroarylpiperazines | HRH3, HRH2, HRH4 | HTR6 35/4885KMT2A 301/4885HPGD 870/4885 |
| US-12624053-B2 | Ras inhibitors | KRAS, NRAS, HMGCR | HTR6 4048/4885KMT2A 3666/4885HPGD 1695/4885 |
| US-20250197423-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | HTR6 4617/4885KMT2A 3685/4885HPGD 3002/4885 |
| US-20250388608-A1 | RAS INHIBITORS | KRAS, NRAS, HMGCR | HTR6 4048/4885KMT2A 3666/4885HPGD 1695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.